Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD
+
) to sustain their survival. This led to the development of inhibitors of nicotinamide (NAM) phosphoribosyltransferase (NAMPT), the rate-limiting NAD
+
biosynthesis enzyme from NAM. Such inhibitors kill cancer cells in preclinical studies but failed in clinica...
Alternative Titles
Full title
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_f655c81b71b94683b6b1d9755f5a5853
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f655c81b71b94683b6b1d9755f5a5853
Other Identifiers
ISSN
2041-4889
E-ISSN
2041-4889
DOI
10.1038/s41419-022-04763-3
